S&P 500   3,038.66 (-2.49%)
DOW   26,251.60 (-2.62%)
QQQ   209.78 (-3.09%)
AAPL   278.21 (-4.93%)
FB   192.00 (-2.64%)
MSFT   162.22 (-4.67%)
GOOGL   1,340.25 (-3.61%)
AMZN   1,908.20 (-3.61%)
CGC   18.80 (-5.15%)
NVDA   259.38 (-3.09%)
BABA   206.46 (-1.09%)
MU   51.68 (-1.32%)
GE   10.65 (-2.74%)
TSLA   685.24 (-12.01%)
AMD   45.13 (-4.97%)
T   36.20 (-2.43%)
ACB   1.45 (-3.98%)
F   7.09 (-1.66%)
NFLX   377.36 (-0.50%)
PRI   117.80 (-1.95%)
BAC   29.66 (-3.17%)
DIS   119.90 (-2.81%)
GILD   72.96 (-2.33%)
S&P 500   3,038.66 (-2.49%)
DOW   26,251.60 (-2.62%)
QQQ   209.78 (-3.09%)
AAPL   278.21 (-4.93%)
FB   192.00 (-2.64%)
MSFT   162.22 (-4.67%)
GOOGL   1,340.25 (-3.61%)
AMZN   1,908.20 (-3.61%)
CGC   18.80 (-5.15%)
NVDA   259.38 (-3.09%)
BABA   206.46 (-1.09%)
MU   51.68 (-1.32%)
GE   10.65 (-2.74%)
TSLA   685.24 (-12.01%)
AMD   45.13 (-4.97%)
T   36.20 (-2.43%)
ACB   1.45 (-3.98%)
F   7.09 (-1.66%)
NFLX   377.36 (-0.50%)
PRI   117.80 (-1.95%)
BAC   29.66 (-3.17%)
DIS   119.90 (-2.81%)
GILD   72.96 (-2.33%)
S&P 500   3,038.66 (-2.49%)
DOW   26,251.60 (-2.62%)
QQQ   209.78 (-3.09%)
AAPL   278.21 (-4.93%)
FB   192.00 (-2.64%)
MSFT   162.22 (-4.67%)
GOOGL   1,340.25 (-3.61%)
AMZN   1,908.20 (-3.61%)
CGC   18.80 (-5.15%)
NVDA   259.38 (-3.09%)
BABA   206.46 (-1.09%)
MU   51.68 (-1.32%)
GE   10.65 (-2.74%)
TSLA   685.24 (-12.01%)
AMD   45.13 (-4.97%)
T   36.20 (-2.43%)
ACB   1.45 (-3.98%)
F   7.09 (-1.66%)
NFLX   377.36 (-0.50%)
PRI   117.80 (-1.95%)
BAC   29.66 (-3.17%)
DIS   119.90 (-2.81%)
GILD   72.96 (-2.33%)
S&P 500   3,038.66 (-2.49%)
DOW   26,251.60 (-2.62%)
QQQ   209.78 (-3.09%)
AAPL   278.21 (-4.93%)
FB   192.00 (-2.64%)
MSFT   162.22 (-4.67%)
GOOGL   1,340.25 (-3.61%)
AMZN   1,908.20 (-3.61%)
CGC   18.80 (-5.15%)
NVDA   259.38 (-3.09%)
BABA   206.46 (-1.09%)
MU   51.68 (-1.32%)
GE   10.65 (-2.74%)
TSLA   685.24 (-12.01%)
AMD   45.13 (-4.97%)
T   36.20 (-2.43%)
ACB   1.45 (-3.98%)
F   7.09 (-1.66%)
NFLX   377.36 (-0.50%)
PRI   117.80 (-1.95%)
BAC   29.66 (-3.17%)
DIS   119.90 (-2.81%)
GILD   72.96 (-2.33%)
Log in

NYSE:CO - Global Cord Blood Stock Price, Forecast & News

$3.98
-0.06 (-1.48 %)
(As of 02/27/2020 03:17 PM ET)
Today's Range
$3.93
Now: $3.99
$4.08
50-Day Range
$4.05
MA: $4.81
$5.11
52-Week Range
$4.05
Now: $3.99
$7.73
Volume106,395 shs
Average Volume71,645 shs
Market Capitalization$484.38 million
P/E Ratio8.86
Dividend YieldN/A
Beta0.17
Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. Read More…

Industry, Sector and Symbol

Industry Holding & other investment offices
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone852-3605-8180

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$147.03 million
Cash Flow$0.39 per share
Book Value$4.20 per share

Profitability

Net Income$43.38 million

Miscellaneous

Employees1,261
Market Cap$484.38 million
Next Earnings Date3/2/2020 (Estimated)
OptionableOptionable

Receive CO News and Ratings via Email

Sign-up to receive the latest news and ratings for CO and its competitors with MarketBeat's FREE daily newsletter.


Global Cord Blood (NYSE:CO) Frequently Asked Questions

What is Global Cord Blood's stock symbol?

Global Cord Blood trades on the New York Stock Exchange (NYSE) under the ticker symbol "CO."

How were Global Cord Blood's earnings last quarter?

Global Cord Blood Corp (NYSE:CO) issued its quarterly earnings data on Tuesday, June, 26th. The medical research company reported $0.04 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.13 by $0.09. The medical research company had revenue of $37.14 million for the quarter. Global Cord Blood had a return on equity of 10.88% and a net margin of 34.86%. View Global Cord Blood's Earnings History.

When is Global Cord Blood's next earnings date?

Global Cord Blood is scheduled to release their next quarterly earnings announcement on Monday, March 2nd 2020. View Earnings Estimates for Global Cord Blood.

Has Global Cord Blood been receiving favorable news coverage?

Headlines about CO stock have been trending very negative recently, InfoTrie Sentiment reports. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Global Cord Blood earned a news sentiment score of -3.7 on InfoTrie's scale. They also assigned media stories about the medical research company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Global Cord Blood.

Are investors shorting Global Cord Blood?

Global Cord Blood saw a decline in short interest in the month of February. As of February 14th, there was short interest totalling 12,700 shares, a decline of 43.8% from the January 30th total of 22,600 shares. Based on an average daily volume of 66,800 shares, the short-interest ratio is currently 0.2 days. Approximately 0.0% of the shares of the stock are short sold. View Global Cord Blood's Current Options Chain.

Who are some of Global Cord Blood's key competitors?

What other stocks do shareholders of Global Cord Blood own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Global Cord Blood investors own include Fate Therapeutics (FATE), Rigel Pharmaceuticals (RIGL), Spero Therapeutics (SPRO), AbbVie (ABBV), Rite Aid (RAD), NovaBay Pharmaceuticals (NBY), Galectin Therapeutics (GALT), Gilead Sciences (GILD), Intel (INTC) and Marvell Technology Group (MRVL).

Who are Global Cord Blood's key executives?

Global Cord Blood's management team includes the folowing people:
  • Ms. Ting Zheng, Chairman, CEO & Interim CEO of Beijing Division (Age 47)
  • Mr. Albert Chen, CFO & Director (Age 43)
  • Ms. Xin Xu, Chief Technology Officer (Age 65)
  • Ms. Rui Arashiyama, Chief Exec. Officer of Guangdong Division & Zhejiang Division (Age 60)
  • Ms. Cathy Bai, VP of Corp. Fin.

Who are Global Cord Blood's major shareholders?

Global Cord Blood's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Jayhawk Capital Management L.L.C. (9.85%), Renaissance Technologies LLC (2.56%), Athos Capital Ltd (0.05%), PEAK6 Investments LLC (0.04%) and Marshall Wace LLP (0.03%). View Institutional Ownership Trends for Global Cord Blood.

Which institutional investors are selling Global Cord Blood stock?

CO stock was sold by a variety of institutional investors in the last quarter, including Jayhawk Capital Management L.L.C. and PEAK6 Investments LLC. View Insider Buying and Selling for Global Cord Blood.

Which institutional investors are buying Global Cord Blood stock?

CO stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Athos Capital Ltd and Marshall Wace LLP. View Insider Buying and Selling for Global Cord Blood.

How do I buy shares of Global Cord Blood?

Shares of CO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Global Cord Blood's stock price today?

One share of CO stock can currently be purchased for approximately $3.99.

How big of a company is Global Cord Blood?

Global Cord Blood has a market capitalization of $484.38 million and generates $147.03 million in revenue each year. Global Cord Blood employs 1,261 workers across the globe.View Additional Information About Global Cord Blood.

What is Global Cord Blood's official website?

The official website for Global Cord Blood is http://www.globalcordbloodcorp.com/.

How can I contact Global Cord Blood?

Global Cord Blood's mailing address is 48 FL. BANK OF CHINA TOWER 1 GARDEN ROAD, HONG KONG K3, . The medical research company can be reached via phone at 852-3605-8180 or via email at [email protected]


MarketBeat Community Rating for Global Cord Blood (NYSE CO)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  242 (Vote Outperform)
Underperform Votes:  231 (Vote Underperform)
Total Votes:  473
MarketBeat's community ratings are surveys of what our community members think about Global Cord Blood and other stocks. Vote "Outperform" if you believe CO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel